- Home
- MHUA vs MIRA Comparison
MHUA vs MIRA Comparison
Compare MHUA & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHUA | MIRA |
|---|---|---|
| Founded | 1990 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.8M | 33.7M |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MHUA | MIRA |
|---|---|---|
| Price | $7.61 | $1.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.4K | ★ 226.7K |
| Earning Date | 12-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 28.96 | N/A |
| Revenue | ★ $89,547,563.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.36 | $0.73 |
| 52 Week High | $67.70 | $2.45 |
Technical Indicators
Market Signals| Indicator | MHUA | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 65.90 |
| Support Level | $11.41 | $1.44 |
| Resistance Level | $14.98 | $1.53 |
| Average True Range (ATR) | 1.54 | 0.08 |
| MACD | 0.36 | 0.02 |
| Stochastic Oscillator | 47.21 | 87.93 |
Price Performance
Historical ComparisonAbout MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.